RT Journal Article
SR Electronic
T1 Predicting severity of Covid-19 using standard laboratory parameters
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.07.21249392
DO 10.1101/2021.01.07.21249392
A1 Thimo Buchmüller
A1 Ingmar Gröning
A1 Ralf Ihl
YR 2021
UL http://medrxiv.org/content/early/2021/01/08/2021.01.07.21249392.abstract
AB Background More than 1.6 million people have already deceased due to a COVID-19 infection making it a major public health concern. A prediction of severe courses can enhance treatment quality and thus lower fatality and morbidity rates. The use of laboratory parameters has recently been established for a prediction. However, laboratory parameters have rarely been used in combination to predict severe outcomes.Method We used a retrospective case-control design to analyze risk factors derived from laboratory parameters. Patients treated for COVID-19 at an hospital in Krefeld, Germany, from March to May 2020 were included (n =42). Patients were classified into two categories based on their outcome (Mild course vs. treatment in intensive care unit). Laboratory parameters were compared across severity categories using non-parametric statistic. Identified laboratory parameters were used in a logistic regression model. The model was replicated using a) clinical standardized parameters b) aggregated factors derived from a factor analysis.Results Patients in intensive care unit showed elevated ALT, CRP and LDH levels, a higher leukocyte and neutrophile count, a higher neutrophile ratio and a lowered lymphocyte ratio. We were able to classify 95.1% of all cases correctly (96.6% of mild and 91.7% of severe cases, p<.001).Conclusion A number of routinely collected laboratory parameters is associated with a severe outcome of COVID-19. The combination of these parameters provides a powerful tool in predicting severity and can enhance treatment effectiveness.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethical commission of the medical faculty of the Heinrich Heine University Duesseldorf gave approval to the study design (Nr. 2020-999).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData can be provided upon request.